These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
111 related articles for article (PubMed ID: 9654191)
1. Chemoattractive effect on the effector cells of the supernatants from melanoma cells transfected with the interleukin-2 (IL-2), IL-4 or IL-6 gene. Cao X; Chen G; He L; Zhang W; Yu Y; Ye TX J Cancer Res Clin Oncol; 1998; 124(2):88-92. PubMed ID: 9654191 [TBL] [Abstract][Full Text] [Related]
2. Involvement of MHC class I molecule and ICAM-1 in the enhancement of adhesion and cytotoxic susceptibility to immune effector cells of tumor cells transfected with the interleukin (IL)-2, IL-4 or IL-6 gene. Cao X; Chen G; He L; Zhang W; Yu Y; Wang J J Cancer Res Clin Oncol; 1997; 123(11-12):602-8. PubMed ID: 9620217 [TBL] [Abstract][Full Text] [Related]
3. Induction of antitumor immunity and treatment of preestablished tumor by interleukin-6-gene-transfected melanoma cells combined with low-dose interleukin-2. Cao X; Zhang W; Gu S; Yu Y; Tao Q; Ye T J Cancer Res Clin Oncol; 1995; 121(12):721-8. PubMed ID: 7499443 [TBL] [Abstract][Full Text] [Related]
4. Antitumor effects on mouse melanoma elicited by local secretion of interleukin-12 and their enhancement by treatment with interleukin-18. Nagai H; Hara I; Horikawa T; Fujii M; Kurimoto M; Kamidono S; Ichihashi M Cancer Invest; 2000; 18(3):206-13. PubMed ID: 10754989 [TBL] [Abstract][Full Text] [Related]
5. Role of effector cell-derived IL-4, IL-5, and perforin in early and late stages of type 2 CD8 effector cell-mediated tumor rejection. Dobrzanski MJ; Reome JB; Dutton RW J Immunol; 2001 Jul; 167(1):424-34. PubMed ID: 11418679 [TBL] [Abstract][Full Text] [Related]
6. Induced Pluripotent Stem Cell-conditioned Medium Suppressed Melanoma Tumorigenicity Through the Enhancement of Natural-Killer Cellular Immunity. Hsieh CT; Luo YH; Chien CS; Wu CH; Tseng PC; Chiou SH; Lee YC; Whang-Peng J; Chen YM J Immunother; 2016 May; 39(4):153-9. PubMed ID: 27023059 [TBL] [Abstract][Full Text] [Related]
7. Elimination of CD4(+) T cells enhances anti-tumor effect of locally secreted interleukin-12 on B16 mouse melanoma and induces vitiligo-like coat color alteration. Nagai H; Hara I; Horikawa T; Oka M; Kamidono S; Ichihashi M J Invest Dermatol; 2000 Dec; 115(6):1059-64. PubMed ID: 11121142 [TBL] [Abstract][Full Text] [Related]
8. Interleukin-10 promotes B16-melanoma growth by inhibition of macrophage functions and induction of tumour and vascular cell proliferation. García-Hernández ML; Hernández-Pando R; Gariglio P; Berumen J Immunology; 2002 Feb; 105(2):231-43. PubMed ID: 11872099 [TBL] [Abstract][Full Text] [Related]
9. Interleukin-18 gene transfer increases antitumor effects of suicide gene therapy through efficient induction of antitumor immunity. Ju DW; Yang Y; Tao Q; Song WG; He L; Chen G; Gu S; Ting CC; Cao X Gene Ther; 2000 Oct; 7(19):1672-9. PubMed ID: 11083476 [TBL] [Abstract][Full Text] [Related]
10. Significant antitumor effects obtained by autologous tumor cell vaccine engineered to secrete interleukin (IL)-12 and IL-18 by means of the EBV/lipoplex. Asada H; Kishida T; Hirai H; Satoh E; Ohashi S; Takeuchi M; Kubo T; Kita M; Iwakura Y; Imanishi J; Mazda O Mol Ther; 2002 May; 5(5 Pt 1):609-16. PubMed ID: 11991752 [TBL] [Abstract][Full Text] [Related]
11. Gene transfer of secreted-type modified interleukin-18 gene to B16F10 melanoma cells suppresses in vivo tumor growth through inhibition of tumor vessel formation. Nagai H; Hara I; Horikawa T; Oka M; Kamidono S; Ichihashi M J Invest Dermatol; 2002 Sep; 119(3):541-8. PubMed ID: 12230493 [TBL] [Abstract][Full Text] [Related]
12. Subcutaneous vaccination with irradiated, cytokine-producing tumor cells stimulates CD8+ cell-mediated immunity against tumors located in the "immunologically privileged" central nervous system. Sampson JH; Archer GE; Ashley DM; Fuchs HE; Hale LP; Dranoff G; Bigner DD Proc Natl Acad Sci U S A; 1996 Sep; 93(19):10399-404. PubMed ID: 8816812 [TBL] [Abstract][Full Text] [Related]
13. CCR5 Blockade Suppresses Melanoma Development Through Inhibition of IL-6-Stat3 Pathway via Upregulation of SOCS3. Tang Q; Jiang J; Liu J Inflammation; 2015 Dec; 38(6):2049-56. PubMed ID: 26047948 [TBL] [Abstract][Full Text] [Related]
14. The tumorigenicity of IL-2 gene-transfected murine M-3D melanoma cells is determined by the magnitude and quality of the host defense reaction: NK cells play a major role. Schneeberger A; Koszik F; Schmidt W; Kutil R; Stingl G J Immunol; 1999 Jun; 162(11):6650-7. PubMed ID: 10352282 [TBL] [Abstract][Full Text] [Related]
15. In vivo elimination of CD25+ regulatory T cells leads to tumor rejection of B16F10 melanoma, when combined with interleukin-12 gene transfer. Nagai H; Horikawa T; Hara I; Fukunaga A; Oniki S; Oka M; Nishigori C; Ichihashi M Exp Dermatol; 2004 Oct; 13(10):613-20. PubMed ID: 15447721 [TBL] [Abstract][Full Text] [Related]
16. [Antitumor effect of interleukin-2 gene-transfected tumor vaccine in combination with interleukin-6 gene-transfected tumor vaccine]. Cao X; Zhang W; Tao Q Zhonghua Yi Xue Za Zhi; 1995 Oct; 75(10):602-5, 639. PubMed ID: 8697075 [TBL] [Abstract][Full Text] [Related]
18. Effective induction of therapeutic antitumor immunity by dendritic cells coexpressing interleukin-18 and tumor antigen. Xia D; Zheng S; Zhang W; He L; Wang Q; Pan J; Zhang L; Wang J; Cao X J Mol Med (Berl); 2003 Sep; 81(9):585-96. PubMed ID: 12937899 [TBL] [Abstract][Full Text] [Related]
19. In vitro and in vivo growth of B16F10 melanoma cells transfected with interleukin-4 cDNA and gene therapy with the transfectant. Ohira T; Ohe Y; Heike Y; Podack ER; Olsen KJ; Nishio K; Nishio M; Miyahara Y; Funayama Y; Ogasawara H J Cancer Res Clin Oncol; 1994; 120(11):631-5. PubMed ID: 7962038 [TBL] [Abstract][Full Text] [Related]
20. Engineered CD8+ cytotoxic T cells with fiber-modified adenovirus-mediated TNF-alpha gene transfection counteract immunosuppressive interleukin-10-secreting lung metastasis and solid tumors. Ye Z; Shi M; Chan T; Sas S; Xu S; Xiang J Cancer Gene Ther; 2007 Jul; 14(7):661-75. PubMed ID: 17479109 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]